On ****, Glon Hui｜Lepu Biotechnology (2157.HK) once rose by 11% to HKD 5.23, hitting a new high in nearly two weeks since May 22nd, with a market cap of nearly HKD 9 billion. Recently, Lepu Biotechnology announced that the results of three clinical studies of innovative candidate drugs and combination therapies will be released at the 2024 ASCO Annual Meeting. The drug candidate combination includes the combination therapy of ADC drug MRG004A, MRG003, and HX008, as well as the combination therapy of HX008 and niraparib. These research results will be presented at the American Society of Clinical Oncology (ASCO) annual meeting in 2024. Bocom International released a research report indicating that in 2024, the State Council's government work report first proposed accelerating the development of innovative drugs, creating new productive forces such as biomanufacturing, and encouraging entrepreneurship and private equity investment. The bank believes that follow-up supporting policies will continue to be introduced to promote the development of medical innovation momentum.
港股异动丨乐普生物一度大涨11% 股价创约两周新高
Hong Kong stock market unusual movements | LPBio rose 11% at one point, and the stock price reached a new high in about two weeks.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.